List of Excipients in Branded Drug RIVIVE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Harm Reduction Therapeutics Inc	RIVIVE	naloxone hydrochloride	82954-0100	HYDROCHLORIC ACID
Harm Reduction Therapeutics Inc	RIVIVE	naloxone hydrochloride	82954-0100	SODIUM CHLORIDE
Harm Reduction Therapeutics Inc	RIVIVE	naloxone hydrochloride	82954-0100	SODIUM HYDROXIDE
Harm Reduction Therapeutics Inc	RIVIVE	naloxone hydrochloride	82954-0100	TRISODIUM CITRATE DIHYDRATE
Harm Reduction Therapeutics Inc	RIVIVE	naloxone hydrochloride	82954-0100	WATER

RIVIVE Excipient Strategy and Commercial Opportunities in Naloxone Nasal Spray

Last updated: August 31, 2026

RIVIVE is a 3 mg naloxone hydrochloride nasal spray approved by the FDA for over-the-counter use. Its commercial position depends less on novel excipients than on reliable nasal delivery, low manufacturing cost, device availability, shelf stability, and distribution into public-health and retail channels. The principal opportunity is to improve access and economics while preserving the simple aqueous formulation and single-use device configuration.

What is RIVIVE and how is it regulated?

RIVIVE is an OTC naloxone hydrochloride nasal spray developed by Harm Reduction Therapeutics, Inc. The FDA approved RIVIVE on July 28, 2023, under NDA 214697. It contains 3 mg of naloxone hydrochloride in a single-use nasal spray device. The product is indicated for the emergency treatment of known or suspected opioid overdose and may be administered to adults and pediatric patients. A second dose may be administered after two to three minutes if the patient does not respond or relapses into respiratory depression. [1][2]

Attribute	RIVIVE
Active ingredient	Naloxone hydrochloride
Strength	3 mg per spray
Dosage form	Single-dose nasal spray
Route	Intranasal
Regulatory pathway	FDA-approved NDA, OTC switch
NDA	214697
Sponsor	Harm Reduction Therapeutics, Inc.
Therapeutic category	Opioid antagonist
Primary use	Emergency reversal of opioid overdose
Pediatric use	Approved for pediatric patients
Biosimilar relevance	None; RIVIVE is a small-molecule drug

RIVIVE competes primarily with Narcan naloxone nasal spray, generic naloxone nasal sprays, injectable naloxone, and other OTC or prescription naloxone products. It does not compete in a conventional chronic-care pharmaceutical market. Demand is driven by public-health procurement, pharmacies, insurers, employers, schools, first responders, correctional facilities, and community organizations.

What excipients are used in RIVIVE?

Public product information identifies RIVIVE as an aqueous naloxone nasal spray containing inactive ingredients used to establish isotonicity, control pH, preserve the formulation, and support product stability. The listed inactive ingredients include sodium chloride, benzalkonium chloride, hydrochloric acid, sodium hydroxide, and purified water. [2]

Excipient	Likely formulation role	Commercial relevance
Sodium chloride	Tonicity adjustment	Low cost; widely available; supports nasal tolerability
Benzalkonium chloride	Antimicrobial preservative	Supports multidose or microbiological control strategy, although RIVIVE is single-use
Hydrochloric acid	pH adjustment	Enables controlled naloxone stability and nasal tolerability
Sodium hydroxide	pH adjustment	Used with acid to establish target formulation pH
Purified water	Vehicle	Standard aqueous pharmaceutical solvent

The public label does not indicate a complex solubilizer, surfactant, mucoadhesive polymer, lipid carrier, cyclodextrin, or nanoparticle system. That simplicity is commercially important. A conventional aqueous formulation reduces raw-material cost, eases scale-up, and limits regulatory risk compared with a reformulation using novel absorption enhancers.

Why is benzalkonium chloride commercially relevant?

Benzalkonium chloride is a long-established preservative, but its use in nasal products requires control of concentration, impurity profile, and tolerability. At excessive exposure, benzalkonium chloride can raise concerns about nasal irritation or mucosal effects. For a single-use emergency product, the preservative may be less central to patient protection than it would be in a multidose bottle.

This creates a potential formulation opportunity. A preservative-free RIVIVE-compatible product could simplify the excipient profile and support positioning for frequent or repeated community use. The opportunity would require stability, microbiological, device, and human tolerability data. It would also create a new regulatory product rather than a simple commercial change.

What is the excipient strategy for RIVIVE?

RIVIVE’s apparent excipient strategy is functional minimalism:

1. Use water as the delivery vehicle.
2. Use sodium chloride to control tonicity.
3. Adjust pH with hydrochloric acid and sodium hydroxide.
4. Use benzalkonium chloride for antimicrobial protection.
5. Avoid specialized absorption-enhancing excipients unless needed for performance.

This strategy fits naloxone’s emergency-use profile. The product must deliver a clinically effective dose rapidly through the nasal mucosa. A formulation that adds complexity without improving onset, dose reliability, shelf life, or device performance would increase cost and regulatory burden.

What formulation attributes matter most?

The most commercially valuable formulation attributes are:

• Rapid and reproducible nasal absorption.
• Stable naloxone concentration over shelf life.
• Consistent spray plume and droplet-size distribution.
• Low extractables and leachables from the container-closure system.
• Acceptable nasal tolerability.
• Resistance to temperature excursions during distribution.
• Compatibility with high-volume, low-cost filling.
• Reliable performance after storage in household and emergency-response environments.

For RIVIVE, the device and formulation cannot be analyzed separately. The delivered dose depends on viscosity, surface tension, pH, osmolality, nozzle geometry, actuation force, priming behavior, and container-closure performance. An excipient change can affect spray characteristics even when the naloxone concentration remains unchanged.

What formulations are protected by RIVIVE-related patents?

RIVIVE’s primary protection is not clearly defined by a publicly prominent formulation-patent estate. The FDA-approved product is associated with NDA 214697, but FDA approval does not itself establish broad patent protection over the formulation, device, or commercial product.

The public FDA label identifies the composition and dosage form. Any patent analysis must distinguish among:

• Patents covering naloxone nasal delivery.
• Patents covering a specific excipient combination.
• Patents covering the spray device.
• Patents covering manufacturing or filling methods.
• Patents covering labeling or method-of-use claims.
• Regulatory exclusivity associated with NDA approval.

What is the Orange Book status of RIVIVE?

RIVIVE is an FDA-approved NDA product rather than an abbreviated new drug application product. The Orange Book is the relevant source for listed patents, exclusivity, and reference-product information. Public FDA records reviewed for the product do not establish a broad, publicly recognized Orange Book patent barrier comparable to the patent estates associated with many specialty drugs. [3]

That distinction matters. If no enforceable, listed patent blocks an ANDA or other competing pathway, the principal barriers become:

• FDA review and approval.
• Product development and human-factor validation.
• Device sourcing.
• Manufacturing capacity.
• Supply-chain qualification.
• Retail and institutional contracting.
• Brand recognition.
• State and local procurement relationships.

The absence of a major listed patent barrier does not mean that competitors can immediately launch. A competitor still must demonstrate pharmaceutical equivalence, device performance, stability, quality, and labeling compliance.

When does RIVIVE lose exclusivity?

RIVIVE’s commercial exclusivity must be separated into three categories: patent exclusivity, regulatory exclusivity, and practical market exclusivity.

Exclusivity category	RIVIVE implication
Patent exclusivity	No broad public patent barrier is apparent from the FDA product record reviewed
NDA regulatory exclusivity	Must be assessed through current FDA Orange Book and Drugs@FDA records
OTC market exclusivity	Limited by the availability of Narcan and other naloxone products
Device or manufacturing exclusivity	May arise from proprietary components, supply contracts, or qualified manufacturing processes
Brand advantage	Can persist after formal exclusivity ends through distribution and procurement relationships

An NDA approval date does not automatically create a durable commercial monopoly. Naloxone has long been an established active ingredient, and competing nasal products can rely on established pharmacology and prior regulatory precedent. The practical competitive moat is therefore likely to come from execution rather than from compound exclusivity.

Are Paragraph IV challenges relevant to RIVIVE?

Paragraph IV litigation is relevant only if a competitor files an ANDA that references RIVIVE and certifies that an identified patent is invalid, unenforceable, or not infringed. Because naloxone nasal spray products may reference different listed products and patent positions, the litigation pathway depends on the specific reference product and current Orange Book entries.

Potential RIVIVE-related challenge scenarios include:

• An ANDA applicant contests a listed formulation patent.
• A competitor contests a device or delivery patent.
• A company seeks approval through an alternative NDA or 505(b)(2) pathway.
• A product uses a different device and formulation, reducing dependence on RIVIVE-specific intellectual property.
• A private-label sponsor enters through a contract-manufactured OTC product.

No publicly established Paragraph IV litigation or settlement agreement is identified here as controlling RIVIVE market entry. Product-specific docket review is required before making a litigation or launch-date conclusion.

Which companies are challenging the RIVIVE market?

The principal competitive threat comes from companies that already sell naloxone or control relevant distribution channels.

Competitor group	Representative participants	Competitive advantage
Branded nasal naloxone	Emergent BioSolutions, through Narcan	Brand recognition, pharmacy presence, OTC experience
Generic nasal naloxone	Generic pharmaceutical manufacturers	Price competition and payer contracting
Injectable naloxone	Multiple manufacturers	Low acquisition cost and institutional familiarity
Public-health suppliers	Distributors and nonprofit procurement channels	Government and community-program access
Private-label OTC sponsors	Consumer-health and pharmacy brands	Retail shelf access and pricing flexibility
Device suppliers	Nasal spray component manufacturers	Control over delivery-system capacity and cost

Narcan’s OTC switch created the clearest benchmark for RIVIVE. RIVIVE’s lower-cost positioning and nonprofit orientation can support public-health procurement, but Narcan has greater consumer awareness and established retail distribution. Generic products can intensify price pressure if they achieve broad pharmacy and institutional adoption.

What commercial opportunities exist for RIVIVE excipients?

The largest opportunities are not likely to come from selling commodity sodium chloride or pH adjusters. They lie in excipient-enabled product differentiation, supply reliability, and reformulation.

Preservative-free nasal naloxone

A preservative-free formulation could reduce excipient exposure and support use in populations receiving repeated naloxone administration. Commercial value would depend on whether the product demonstrates equal or better stability, microbiological control, nasal tolerability, and device performance.

Improved nasal absorption

Absorption-enhancing excipients could permit a lower nominal dose, faster onset, or improved performance in patients with nasal congestion. Candidates could include mucoadhesive polymers, surfactants, cyclodextrins, or other approved nasal excipients. These approaches carry higher development risk because they can affect mucosal tolerability and may require new clinical bridging studies.

Temperature-stable formulations

Naloxone distribution often includes vehicles, ambulances, shelters, schools, police vehicles, and outdoor environments. A formulation with stronger resistance to heat and freeze-thaw excursions could reduce product loss and simplify inventory management. Excipient selection, container-closure design, and packaging would all contribute.

Child-friendly and accessibility-focused delivery

RIVIVE is approved for pediatric use, but practical administration remains important. Commercial opportunities include lower-actuation-force devices, clearer visual instructions, tactile differentiation, and packaging that reduces misuse. These changes are primarily device and human-factors opportunities, but formulation viscosity and spray behavior remain relevant.

Regional and contract-manufacturing supply

Naloxone demand is sensitive to public-health funding, opioid mortality trends, and government purchasing programs. A second-source excipient and component strategy could reduce supply interruptions. Manufacturers that qualify multiple suppliers for sodium chloride, preservative, primary packaging, and spray pumps may gain an advantage in institutional tenders.

How does RIVIVE compare with Narcan?

Factor	RIVIVE	Narcan
Active ingredient	Naloxone hydrochloride	Naloxone hydrochloride
Nasal dose	3 mg	4 mg
OTC status	FDA-approved OTC	FDA-approved OTC
Core market	Public health, retail, community access	Retail, public health, emergency use
Formulation profile	Simple aqueous formulation disclosed in labeling	Established aqueous nasal formulation
Brand recognition	Lower	Higher
Commercial positioning	Access and affordability	Brand scale and distribution
Patent risk	Requires current Orange Book review	More established product-specific patent history
Differentiation	Price, access, procurement, supply	Brand, availability, consumer familiarity

Dose strength alone does not determine clinical or commercial superiority. Device reliability, nasal deposition, absorption, packaging, price, and availability are more relevant to real-world use.

What manufacturing and intellectual-property barriers affect RIVIVE?

The main manufacturing barriers are likely to be operational rather than raw-material scarcity. A commercial supplier must control:

• Naloxone assay and impurity levels.
• Solution pH and osmolality.
• Preservative concentration.
• Sterility or microbiological quality controls.
• Pump delivery volume.
• Spray pattern and plume geometry.
• Container-closure integrity.
• Extractables and leachables.
• Stability under long-term and accelerated conditions.
• Automated filling and assembly throughput.

Device supply can become a larger constraint than excipient supply. Nasal spray pumps require specialized tooling, quality controls, and assembly capacity. A company with a validated spray platform and available manufacturing slots may be more commercially valuable than a company offering a marginally improved excipient system.

What is the FDA regulatory outlook for RIVIVE competitors?

Competitors can pursue several pathways:

• ANDA approval when the reference product and device requirements permit.
• A 505(b)(2) NDA for a materially different formulation, device, or route-specific product.
• A new NDA for an innovative naloxone delivery system.
• OTC labeling supported by FDA’s nonprescription requirements.
• Institutional or prescription commercialization where OTC positioning is not used.

A formulation change involving a new absorption enhancer, preservative system, or delivery device could trigger additional clinical, human-factors, or local-tolerability requirements. A simple excipient substitution may still require comparative quality, stability, and performance evidence.

What generic launch risks exist for RIVIVE?

RIVIVE faces several generic-entry scenarios:

1. A lower-priced nasal spray obtains FDA approval using an established reference-product pathway.
2. A contract manufacturer supplies private-label naloxone to major pharmacy chains.
3. A generic manufacturer wins a state or federal procurement contract without establishing strong retail presence.
4. A competing product uses a different device and avoids RIVIVE-specific intellectual property.
5. Injectable naloxone continues to undercut nasal products in institutional settings.

The highest-risk scenario for RIVIVE is not necessarily a patent defeat. It is rapid price compression combined with a competitor that has superior device supply, retail distribution, or government contracting access.

What licensing deals could create value around RIVIVE?

Licensing opportunities exist in four areas:

• Nasal spray device platforms.
• Preservative-free or absorption-enhanced formulations.
• Contract manufacturing and fill-finish capacity.
• Regional distribution and public-health procurement.

A formulation license is most attractive if it offers measurable value, such as improved shelf life, reduced nasal irritation, better spray performance, or lower manufacturing cost. A license covering only commodity excipients is unlikely to create a durable moat unless it is paired with formulation know-how, process controls, or patent claims.

Key Takeaways

• RIVIVE is a 3 mg OTC naloxone hydrochloride nasal spray approved under NDA 214697.
• Its public excipient profile is simple: sodium chloride, benzalkonium chloride, hydrochloric acid, sodium hydroxide, and purified water.
• The formulation strategy emphasizes low complexity, nasal delivery, stability, and manufacturability.
• The strongest commercial opportunities involve preservative-free products, improved stability, device optimization, lower manufacturing cost, and reliable institutional supply.
• RIVIVE’s competitive exposure comes from Narcan, generic nasal naloxone, injectable naloxone, and private-label OTC products.
• No broad public patent barrier is apparent from the FDA product record reviewed, but current Orange Book entries and litigation dockets control any definitive launch analysis.
• Device capacity, public-health procurement, and retail distribution may matter more than excipient novelty.
• Biosimilar risk does not apply because naloxone is a small-molecule drug.

FAQs

Does RIVIVE contain a nasal absorption enhancer?

The public labeling identifies a conventional aqueous formulation and does not identify a specialized mucoadhesive or absorption-enhancing excipient.

Is RIVIVE preservative-free?

Public product information identifies benzalkonium chloride as an inactive ingredient. RIVIVE therefore should not be treated as a preservative-free formulation.

Can a generic manufacturer copy RIVIVE’s excipients?

A competitor may be able to use the same excipients, subject to applicable patent rights, regulatory requirements, quality standards, and product-performance obligations. Excipients themselves generally do not create exclusivity when used in established pharmaceutical roles.

Could RIVIVE be sold under private-label pharmacy brands?

Private-label commercialization is commercially plausible if the sponsor secures an FDA-compliant product, manufacturing arrangement, device supply, labeling strategy, and distribution agreement.

Is an injectable naloxone product a direct substitute for RIVIVE?

Injectable naloxone is a therapeutic substitute but has different administration requirements, training needs, packaging, and procurement economics. Nasal naloxone has a practical advantage in community and layperson administration.

References

1. U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray

2. U.S. Food and Drug Administration. (2023). RIVIVE naloxone hydrochloride nasal spray, 3 mg: Prescribing information. Drugs@FDA, NDA 214697. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2023). RIVIVE approval letter, NDA 214697. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.